Pulmonary drug delivery is used to treat diseases in the airways by delivering locally acting drugs directly to their site of action. This routes of drug delivery offer advantages such as small amount of drug, less adverse reaction and rapid onset of action. Pulmonary delivery of drugs has developed into an attractive target in the health care industry as the lung is capable of absorbing drugs faster. Devices used to deliver drugs by pulmonary route are pressurized metered dose inhaler, nebulizer and dry powder. Pulmonary drug delivery is an important research area which impacts the treatment including asthma, chronic obstructive pulmonary disease and various diseases.
Key driver for growth of the global pulmonary drug delivery systems market is rising prevalence of respiratory chronic such as tuberculosis, bronchitis and chronic obstructive pulmonary disease, increasing demand for non-invasive methods, technological advancements such smart inhaler, increase in smoking, increasing geriatrics population, and change in lifestyle. However, regulatory approvals and patent expiration of blockbuster drugs may hinder growth of the global market.
Recent trend in applications of pulmonary drug delivery include insulin by aerosol, treatment of migraine, nicotine aerosol for smoking cessation, aerosols for angina, aerosol vaccination and inhaled drug delivery for tuberculosis therapy. Nanoparticles (NPs) are emerging effective targeted drug delivery systems because of their non-invasive approach and lesser bioavailability in the systemic circulation.
Do Inquiry of the Report Here: https://marketresearch.biz/report/pulmonary-drug-delivery-systems-market/#inquiry
The pulmonary drug delivery systems market report has been segmented on the basis of product, application, distribution channel and region. North America market is estimated to dominate the pulmonary drug delivery systems market, owing to increase growing prevalence of lung and respiratory diseases, which is expected to boost growth of the market in this region. Market in Asia Pacific is the emerging market for pulmonary drug delivery systems market due to presence of various players focusing on the development of inhaler products.
Prominent market players in the global pulmonary drug delivery systems market include GlaxoSmithKline plc, Merck & Co., Inc., Sunovion Pharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Omron Healthcare, Inc., Skyepharma Plc, CareFusion Corporation, and Philips Respironics Inc.